259 related articles for article (PubMed ID: 24965290)
1. Univariate analysis to examine predictors of response to leukocytapheresis in ulcerative colitis patients.
Nagayama K; Takedatsu H; Mitsuyama K; Yamasaki H; Kuwaki K; Yoshioka S; Kobayashi T; Yamauchi R; Kakuma T; Sata M
Ther Apher Dial; 2014 Jun; 18(3):244-51. PubMed ID: 24965290
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Ashida T; Kohgo Y; Munakata A; Noguchi M; Iizuka B; Endo Y; Hanai H; Yoshikawa T; Matsumoto T; Aoyama N; Matsui T; Mitsuyama K; Hibi T
Transfus Apher Sci; 2011 Apr; 44(2):113-7. PubMed ID: 21402309
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis.
Shimada M; Iwase H; Tsuzuki T; Hirashima N; Kobayashi K; Hibino Y; Watanabe H; Ryuge N; Ando T; Goto H; Yagi Y; Tsujikawa T; Andoh A
Ther Apher Dial; 2008 Oct; 12(5):368-73. PubMed ID: 18937719
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study.
Sakata Y; Iwakiri R; Amemori S; Yamaguchi K; Fujise T; Otani H; Shimoda R; Tsunada S; Sakata H; Ikeda Y; Ando T; Nakafusa Y; Fujimoto K
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):629-33. PubMed ID: 18679064
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.
Kobayashi T; Matsuoka K; Yokoyama Y; Nakamura T; Ino T; Numata T; Shibata H; Aoki H; Matsuno Y; Hibi T
J Gastroenterol; 2018 Mar; 53(3):387-396. PubMed ID: 28597225
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis.
Nakano R; Iwakiri R; Ikeda Y; Kishi T; Tsuruoka N; Shimoda R; Sakata Y; Yamaguchi K; Fujimoto K
J Gastroenterol Hepatol; 2013 Feb; 28(2):303-8. PubMed ID: 23339387
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of five days of consecutive leukocytapheresis for the treatment of ulcerative colitis: a preliminary study.
Tsujikawa T; Andoh A; Ogaẃa A; Sonoda A; Yagi Y; Hata K; Sasaki M; Saito Y; Fujiyama Y
Ther Apher Dial; 2009 Feb; 13(1):14-8. PubMed ID: 19379165
[TBL] [Abstract][Full Text] [Related]
8. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy.
Nishioka C; Aoyama N; Maekawa S; Shirasaka D; Nakahara T; Tamura T; Fukagawa M; Umezu M; Abe T; Kasuga M
J Gastroenterol Hepatol; 2005 Oct; 20(10):1567-71. PubMed ID: 16174075
[TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Matsumoto T; Andoh A; Okawa K; Ito H; Torii A; Yoshikawa S; Nakaoka R; Okuyama Y; Oshitani N; Nishishita M; Watanabe K; Fukunaga K; Ohnishi K; Kusaka T; Yokoyama Y; Sasaki M; Tsujikawa T; Aoki T; Kusaka T; Takeda Y; Umehara Y; Nakamura S; Fujiyama Y
Ther Apher Dial; 2008 Dec; 12(6):484-90. PubMed ID: 19140847
[TBL] [Abstract][Full Text] [Related]
10. Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis.
Okuyama Y; Andoh A; Nishishita M; Fukunaga K; Kamikozuru K; Yokoyama Y; Ueno Y; Tanaka S; Kuge H; Yoshikawa S; Sugahara A; Anami E; Munetomo Y; Watanabe C; Fujiyama Y; Matsumoto T
Scand J Gastroenterol; 2013 Apr; 48(4):412-8. PubMed ID: 23356660
[TBL] [Abstract][Full Text] [Related]
11. Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with Cellsorba in patients with active ulcerative colitis.
Fukunaga K; Kamikozuru K; Yokoyama Y; Hida N; Ohda Y; Takeda N; Yoshida K; Iimuro M; Kikuyama R; Kato K; Nagase K; Nakamura S; Miwa H; Matsumoto T
J Clin Apher; 2011 Dec; 26(6):326-31. PubMed ID: 22083887
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis.
Umehara Y; Kudo M; Kawasaki M
World J Gastroenterol; 2008 Sep; 14(34):5316-21. PubMed ID: 18785285
[TBL] [Abstract][Full Text] [Related]
13. Leukocytapheresis in pediatric patients with ulcerative colitis.
Tomomasa T; Tajiri H; Kagimoto S; Shimizu T; Yoden A; Ushijima K; Uchida K; Kaneko H; Abukawa D; Konno M; Maisawa S; Kohsaka T; Kobayashi A;
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):34-9. PubMed ID: 21694533
[TBL] [Abstract][Full Text] [Related]
14. Relationship between ulcerative colitis patients treated with leukocytapheresis and ulcerative colitis-associated colorectal cancer.
Kinugasa T; Akagi Y; Murotani K; Romeo K; Yoshida T; Ryu Y; Shiratuchi I; Shirouzu K
Anticancer Res; 2011 Jul; 31(7):2547-52. PubMed ID: 21873173
[TBL] [Abstract][Full Text] [Related]
15. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Sawada K; Kusugami K; Suzuki Y; Bamba T; Munakata A; Hibi T; Shimoyama T
Am J Gastroenterol; 2005 Jun; 100(6):1362-9. PubMed ID: 15929771
[TBL] [Abstract][Full Text] [Related]
16. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.
Fukunaga K; Fukuda Y; Yokoyama Y; Ohnishi K; Kusaka T; Kosaka T; Hida N; Ohda Y; Miwa H; Matsumoto T
J Gastroenterol; 2006 Jun; 41(6):524-32. PubMed ID: 16868799
[TBL] [Abstract][Full Text] [Related]
17. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial.
Emmrich J; Petermann S; Nowak D; Beutner I; Brock P; Klingel R; Mausfeld-Lafdhiya P; Liebe S; Ramlow W
Dig Dis Sci; 2007 Sep; 52(9):2044-53. PubMed ID: 17410456
[TBL] [Abstract][Full Text] [Related]
18. LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS.
Krznarić Ž; Markoš P; Golubić Ćepulić B; Čuković-Čavka S; Domislović V; Bojanić I; Barišić A; Kekez D
Acta Clin Croat; 2019 Sep; 58(3):529-534. PubMed ID: 31969767
[TBL] [Abstract][Full Text] [Related]
19. Influence of leukocytapheresis therapy for ulcerative colitis on anemia and hemodynamics.
Miyamoto H; Okahisa T; Iwaki H; Murata M; Ito S; Nitta Y; Akutagawa M; Kinouchi Y; Ohnishi Y; Oto J; Nishimura M
Ther Apher Dial; 2007 Feb; 11(1):16-21. PubMed ID: 17309570
[TBL] [Abstract][Full Text] [Related]
20. [Leukocytapheresis for ulcerative colitis].
Fukunaga K; Sawada K; Chikano S; Ohnishi K; Egashira A; Tanaka J; Nagase K; Satomi M; Shimoyama T
Nihon Rinsho; 1999 Nov; 57(11):2496-502. PubMed ID: 10572419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
